[1]唐武兵,楊 文,陳健智,等.尼妥珠單抗聯合調強適形放療及化療治療局部晚期肺鱗癌的研究[J].醫學信息,2019,(20):1-4.[doi:10.3969/j.issn.1006-1959.2019.20.001]
 TANG Wu-bing,YANG Wen,CHEN Jian-zhi,et al.Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma[J].Medical Information,2019,(20):1-4.[doi:10.3969/j.issn.1006-1959.2019.20.001]
點擊復制

尼妥珠單抗聯合調強適形放療及化療治療局部晚期肺鱗癌的研究()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
1-4
欄目:
肺癌與肺損傷專題
出版日期:
2019-10-15

文章信息/Info

Title:
Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma
文章編號:
1006-1959(2019)20-0001-04
作者:
唐武兵1楊 文1陳健智2潘興喜1陳永發1伍楚蓉1袁燕玲1童麗華1
(南方醫科大學附屬南海醫院腫瘤一科1,病理科2,廣東 佛山 528200)
Author(s):
TANG Wu-bing1YANG Wen1CHEN Jian-zhi2PAN Xing-xi1CHEN Yong-fa1WU Chu-rong1YUAN Yan-ling1TONG Li-hua1
(Department of Oncology,Subject One1,Department of Pathology2,Nanhai Hospital,Southern Medical University,Foshan 528200,Guangdong,China)
關鍵詞:
非小細胞肺癌放射治療化學治療尼妥珠單抗靶向治療表皮生長因子受體
Keywords:
Non-small cell lung cancerRadiotherapyChemotherapyNimotuzumabTargeted therapy Epidermal growth factor receptor
分類號:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.20.001
文獻標志碼:
A
摘要:
目的 探討尼妥珠單抗聯合調強適形放療(IMRT)及化療治療局部晚期肺鱗癌的臨床療效。方法 選取2015年1月~2018年12月我院經組織病理確診為肺鱗癌且免疫組織化學檢查表達EGFR的Ⅲa~Ⅲb期患者58例,采用隨機數字表法分為對照組(n=28)和觀察組(n=30)。對照組采用IMRT及化療治療,觀察組在對照組基礎上聯合尼妥珠單抗治療,比較兩組EGFR表達、近期療效、不良反應及遠期療效。結果 兩組EGFR表達比較,差異無統計學意義(P>0.05)。觀察組總有效率(ORR)高于對照組(73.33% vs 46.43%),疾病控制率(DCR)高于對照組(96.67% vs 67.86%),差異有統計學意義(P<0.05)。兩組白細胞下降、血紅蛋白下降、血小板下降、胃腸道反應、肝功能異常、腎功能異常、放射性肺炎、放射性食管炎比較,差異無統計學意義(P>0.05)。觀察組無進展生存期(PFS)和總生存期(OS)較對照組延長,差異有統計學意義(P<0.05)。結論 尼妥珠單抗聯合IMRT及化療治療局部晚期肺鱗癌,可有效改善患者的治療有效率和病情控制效果,且不良反應低,耐受性好,遠期療效較好。
Abstract:
Objective To investigate the efficacy of nimotuzumab combined with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced lung squamous cell carcinoma.Methods From January 2015 to December 2018, 58 patients with stage IIIa~IIIb who were diagnosed as lung squamous cell carcinoma and immunohistochemically examined for EGFR were enrolled in our hospital. The patients were randomly divided into control group (n=28)and observation group (n=30). The control group was treated with IMRT and chemotherapy. The observation group was treated with rituximab in the control group. The EGFR expression, short-term efficacy, adverse reactions and long-term efficacy were compared between the two groups.Results There was no significant difference in EGFR expression between the two groups (P>0.05). The ORR of the observation group was higher than that of the control group (73.33% vs 46.43%), and the DCR was higher than that of the control group (96.67% vs 67.86%),the difference was statistically significant (P<0.05). There were no significant differences in white blood cell decline, hemoglobin decline, thrombocytopenia, gastrointestinal reactions, liver dysfunction, renal dysfunction, radiation pneumonitis, and radiation esophagitis between the two groups (P>0.05). The PFS and OS in the observation group were longer than those in the control group,the difference was statistically significant (P<0.05).Conclusion Nimotuzumab combined with IMRT and chemotherapy for locally advanced lung squamous cell carcinoma can effectively improve the treatment efficiency and disease control effect, and has low adverse reactions, good tolerance and good long-term efficacy.

參考文獻/References:

[1]Xu S,Ramos-Suzarte M,Bai X,et al.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients:a single institute experience[J].Oncotarget,2016,7(22):33391-33407. [2]de Castro Junior G,Segalla JG,de Azevedo SJ,et al.A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer:NICE trial[J].Eur J Cancer,2018,88(1):21-30. [3]Subramanian S,Sridharan N,Balasundaram V,et al.Effectiveness and tolerability of nimotuzumab in unresectable,locally advanced/metastatic esophageal cancer:Indian hospital-based retrospective evidence[J].South Asian J Cancer,2019,8(2):112-115. [4]Chen YF,Tang WB,Pan XX,et al.Safety and efficacy of nimotuzumab combined with hemoradiotherapy in Chinese patients with locally advanced cervical cancer[J].Onco Targets Ther,2017(10):4113-4119. [5]Du XJ,Li XM,Cai LB,et al.Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma:a phase Ⅱ multicenter clinical trial[J].J Cancer,2019,10(14):3214-3223. [6]張坤寧,路軍,趙宏穎,等.表皮生長因子受體、人類表皮生長因子受體2、人類表皮生長因子受體3表達與非小細胞肺癌預后的關系[J].腫瘤研究與臨床,2016,28(2):73-89. [7]周際昌.實用腫瘤內科治療(第2版)[M].北京:北京科學技術出版社,2016. [8]李曄雄.腫瘤放射治療學(第5版)[M].北京:中國協和醫科大學出版社,2018. [9]蘇寧,張賢蘭,黃惠怡,等.晚期肺腺癌驅動基因分布及其一線治療現狀-單中心真實世界研究[J].實用醫學雜志,2019,35(4):537-540. [10]張童童,李峻嶺.存在驅動基因突變肺鱗癌患者的臨床病理特征及預后分析[J].中國肺癌雜志,2016,19(10):648-652. [11]Concha-Benavente F,Ferris RL.Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy[J].Frontiers in Pharmacology,2017(8):332. [12]Zhu J,Xin Y,Liu X,et al.Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-кB signaling pathway[J].Experimental and Therapeutic Medicine,2018(5):3345-3351. [13]Garrido G,Rabasa A,Garrido C,et al.Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab[J].Front Pharmacol,2017(8):595. [14]Kato K,Ura T,Koizumi W,et al.Nimotuzumab combined with concurrent hemoradiotherapy in Japanese patients with esophageal cancer:A phase I study[J].Cancer Science,2018,109(3):785-793. [15]Peng H,Tang LL,Liu X,et al.Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma:a big-data,intelligence platform-based analysis[J].BMC Cancer,2018,18(1):323. [16]Zhao J,Zhuo M,Wang Z,et al.A phase Ⅰ study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer[J].Chinese Journal of Cancer Research,2016,28(1):12-18. [17]Li J,Yan H.Skin toxicity with anti-EGFR monoclonal antibody in cancer patients:a meta-analysis of 65 randomized controlled trials[J].Cancer Chemother Pharmacol,2018,82(4):571-583.

相似文獻/References:

[1]田 亮,郭 楠,苗志剛,等.非小細胞肺癌中ZEB1和FoxO3a表達及意義[J].醫學信息,2018,(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
 TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,(20):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孫國平.非小細胞肺癌根治術后復發及進展影響因素的回顧性分析[J].醫學信息,2018,(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
 TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,(20):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]許益芬.三維適型放療與調強放療在胸中段食管癌根治性放療中的 劑量學比較[J].醫學信息,2018,(13):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
 XU Yi-fen.Dosimetric Comparison of Three-dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Radical Radiotherapy of Middle Thoracic Esophageal Carcinoma[J].Medical Information,2018,(20):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
[4]李春磊,裴艷志,鄒志田,等.非小細胞肺癌組織中趨化因子受體CCR7的 表達及其臨床意義[J].醫學信息,2018,(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
 LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,(20):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]楊 莉.TP方案聯合回生口服液治療中晚期非小細胞肺癌的療效觀察[J].醫學信息,2018,(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
 YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,(20):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]田春琴,趙新漢,蔣冬梅,等.二線用藥EGFR-TKIs治療非選擇型NSCLC療效的Meta分析[J].醫學信息,2018,(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
 TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐聞霞,陸紅艷,黃 斌.胸腔鏡肺葉切除和肺段切除治療ⅠA期非小細胞肺癌的療效比較[J].醫學信息,2018,(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
 XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,(20):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付紅星,馮小劍,彭文苗,等.康艾注射液聯合化療治療晚期非小細胞肺癌的臨床研究[J].醫學信息,2018,(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
 FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,(20):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]吳森林,高 斌.中性粒細胞/淋巴細胞比值與介入治療中晚期非小細胞肺癌患者預后的相關性[J].醫學信息,2019,(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
 WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,(20):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[10]賈殿軍,王利軍,程險峰,等.可手術的非小細胞肺癌患者外周靜脈血cfDNA總濃度及長片段DNA濃度的臨床價值研究[J].醫學信息,2019,(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
 JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,(20):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图